Journal article Open Access

T Lymphocyte-Directed Gene Therapy for ADA-SCID: Initial Trial Results After 4 Years

Blaese, R. Michael; Culver, Kenneth W.; Miller, A. Dusty; Shearer, G.; Carter, Charles S.; Clerici, M.; Tolstoshev, P.; Fleisher, Thomas; Chang, L.; Rosenberg, S. A.; Chiang, Y.; Mullen, C. A.; Greenblatt, J. J.; Ramsey, W. J.; Klein, H.; Muul, L.; Berger, M.; Morgan, R. A.; Anderson, W. F.

In 1990, a clinical trial was started using retroviral-mediated transfer of the adenosine deaminase (ADA) gene into the T cells of two children with severe combined immunodeficiency (ADA− SCID). The number of blood T cells normalized as did many cellular and humoral immune responses. Gene treatment ended after 2 years, but integrated vector and ADA gene expression in T cells persisted. Although many components remain to be perfected, it is concluded here that gene therapy can be a safe and effective addition to treatment for some patients with this severe immunodeficiency disease.
Files (2.0 MB)
Name Size
2.0 MB Download
Views 1,431
Downloads 1,232
Data volume 2.4 GB
Unique views 1,319
Unique downloads 1,157


Cite as